Dropped‐head syndrome in a patient under treatment with the MEK inhibitor trametinib for NRAS‐mutated metastatic melanoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2230|43|2|195-196

ISSN： 0307-6938

Source： CLINICAL & EXPERIMENTAL DERMATOLOGY, Vol.43, Iss.2, 2018-03, pp. : 195-196

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinib

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 32, Iss. 1, 2018-01 ,pp. : e31-e32

John Wiley & Sons Inc

Access to resources Recommend Favorite

The dropped head syndrome: rehabilitation of cervical focal myositis

By Bahnof Roy  

Disability and Rehabilitation, Vol. 21, Iss. 12, 1999-12 ,pp. : 563-565

Informa Healthcare

Access to resources Recommend Favorite

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3821-3829

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of the Effects of Food on the Single‐Dose Pharmacokinetics of Trametinib, a First‐in‐Class MEK Inhibitor, in Patients with Cancer

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 53, Iss. 9, 2013-09 ,pp. : 946-954

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient

By  

Case Reports in Oncology, Vol. 6, Iss. 2, 2013-05 ,pp. : 285-288

Karger

Access to resources Recommend Favorite